When to Start Growth Hormone Therapy for Noonan Syndrome

Growth hormone (GH) therapy is an established, effective treatment for the short stature commonly associated with Noonan syndrome. The best time to start treatment is typically when a child’s growth slows down significantly and drops below the expected curve for their age—often between the ages of 4 and 8 ^[1]. Starting at a younger age (usually before puberty) generally leads to a better overall response and better final height ^[2][1].

However, the exact timing must be highly personalized. Doctors may delay starting therapy if the child has specific genetic risks or pre-existing heart conditions that need to be stabilized first ^[3][4].

What to Expect: The Daily Commitment

Growth hormone is a manufactured (recombinant) version of the natural hormone. Because children with Noonan syndrome often have some “insensitivity” or resistance to growth hormones, they typically require higher doses than children who simply do not produce enough hormone on their own ^[5][6].

Treatment requires a significant commitment: it is currently given as a subcutaneous injection (a shot just under the skin) every single day at home. While the idea of daily injections can be daunting for parents, the process is very manageable. Modern auto-injector pens use extremely thin, short needles, and most young children adapt to the routine remarkably fast with minimal discomfort.

(Note: Newer once-weekly long-acting growth hormone formulations are becoming available, but daily injections remain the standard, most heavily researched approach for syndromic short stature. Your doctor can discuss if weekly options are appropriate.)

How Your Endocrinologist Monitors Progress

Once therapy begins, your child will see a pediatric endocrinologist regularly (usually every 3 to 6 months). Before starting, the doctor might also recommend a sleep study to check for obstructive sleep apnea, as rapid growth can sometimes worsen airway issues.

Routine monitoring includes:

• Growth Velocity: Tracking how fast the child is growing compared to specialized Noonan syndrome growth curves ^[2].
• Bone Age X-Rays: Periodic x-rays of the hand and wrist to check bone age (a measure of how quickly the skeleton is maturing). This helps the doctor predict final adult height and ensure the bones aren’t maturing too rapidly.
• Blood Tests: Regular lab work is crucial. The doctor will check IGF-1 (a hormone reflecting how well the growth hormone is working) to ensure the dose is safe. They will also monitor blood glucose (sugar) levels, as growth hormone therapy can sometimes increase insulin resistance.
• Heart Health: Close coordination with a pediatric cardiologist is essential. For children with hypertrophic cardiomyopathy (HCM, a thickening of the heart muscle), GH therapy is often still possible, but it must be monitored closely ^[7][8]. Growth hormone can potentially cause the heart muscle to thicken further (worsening left ventricular outflow tract stenosis). If echocardiograms show negative changes, therapy may need to be adjusted or paused.
• Spinal Checks: Monitoring for the development or worsening of scoliosis (curvature of the spine), which can happen during periods of rapid growth ^[9][10].

Proven Impact on Final Adult Height

Research shows that GH therapy effectively increases growth velocity during the first few years of treatment and meaningfully improves final adult height ^[2][11]. Over a four-year period, treated children have shown significant height improvements—roughly +1.14 to +1.48 standard deviations compared to both typical national charts and Noonan-specific charts ^[2]. While individual results vary, this generally translates to gaining several extra inches of adult height.

Importantly, studies indicate that the therapy improves final height regardless of which specific genetic mutation (such as PTPN11, SOS1, or RAF1) caused the Noonan syndrome ^[12][11].

Balancing Benefits and Risks

Before starting therapy, your medical team will carefully evaluate your child’s overall health.

• Immediate Side Effects: Although rare, parents should watch for severe headaches, unexplained nausea or vomiting, or visual changes shortly after starting therapy. These can be signs of benign intracranial hypertension (increased pressure around the brain), a serious but reversible side effect of pediatric growth hormone therapy. Contact your medical team immediately if these occur.
• Cancer Risk Considerations: Some children with Noonan syndrome (particularly those with specific PTPN11 mutations) have a slightly increased risk for certain very rare blood conditions, such as juvenile myelomonocytic leukemia (JMML). While JMML is exceedingly rare overall, growth hormone stimulates cell growth, so doctors exercise extra caution ^[13][4]. They will often wait to start GH therapy until they are certain the child’s cancer risk profile is stable. Families should have open discussions with their care team about these risks to make a confident, personalized decision ^[14].